Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Journal of Neurosurgical Anesthesiology

Volumn 23, Issue 4, 2011, Pages 310-317

  Suzuki, Hidenori ^a   Kanamaru, Kenji ^a   Shiba, Masato ^a   Fujimoto, Masashi ^a   Imanaka Yoshida, Kyoko ^b   Yoshida, Toshimichi ^b   Taki, Waro ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suzuka Kaisei Hospital   (Japan)

Author keywords

cerebral vasospasm; cerebrospinal fluid; extracellular matrix; outcome; subarachnoid hemorrhage; tenascin C

Indexed keywords

TENASCIN;

ADULT; AGED; ARTICLE; BRAIN VASOSPASM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; SUBARACHNOID HEMORRHAGE; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CEREBRAL ANGIOGRAPHY; FEMALE; HUMANS; HYDROCEPHALUS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; SUBARACHNOID HEMORRHAGE; SURGICAL INSTRUMENTS; TENASCIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 80052735039     PISSN: 08984921     EISSN: 15371921     Source Type: Journal    
DOI: 10.1097/ANA.0b013e31822aa1f2     Document Type: Article

References (42)

1. Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery. 2001;48:249-262. (Pubitemid 32164863)
2. Lysakowski C, Walder B, Costanza MC, et al. Transcranial Doppler versus angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systemic review. Stroke. 2001;32:2292-2298. (Pubitemid 32954797)
3. Matsui Y, Morimoto J, Uede T. Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J Biol Chem. 2010;1:69-80.
4. Suzuki H, Kanamaru K, Suzuki Y, et al. Possible role of tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2008;104:179-182.
5. Suzuki H, Kinoshita N, Imanaka-Yoshida K, et al. Cerebrospinal fluid tenascin-C increases preceding the development of chronic shunt-dependent hydrocephalus after subarachnoid hemorrhage. Stroke. 2008;39:1610-1612.
6. Suzuki H, Kanamaru K, Suzuki Y, et al. Tenascin-C is induced in cerebral vasospasm after subarachnoid hemorrhage in rats and humans: a pilot study. Neurol Res. 2010;32:179-184.
7. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1-9. (Pubitemid 10159923)
8. Drake CG. Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68:985-986. Letter.
9. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-484.
10. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29-36. (Pubitemid 12142173)
11. Jordan JD, Nyquist P. Biomarkers and vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am. 2010;21:381-391.
12. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery. 2003;53:123-135. (Pubitemid 36801515)
13. Borel CO, McKee A, Parra A, et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke. 2003;34:427-433.
14. Ohkuma H, Tsurutani H, Suzuki S. Changes of beta-actin mRNA expression in canine vasospastic basilar artery after experimental subarachnoid hemorrhage. Neurosci Lett. 2001; 311:9-12. (Pubitemid 32831490)
15. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid hemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70:534-537. (Pubitemid 32269696)
16. Maurer MH, Haux D, Sakowitz OW, et al. Identification of early markers for symptomatic vasospasm in human cerebral microdia-lysate after subarachnoid hemorrhage: preliminary results of a proteome-wide screening. J Cereb Blood Flow Metab. 2007;27: 1675-1683. (Pubitemid 47476094)
17. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol. 2003;200: 488-499. (Pubitemid 36818249)
18. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol. 2004;36: 986-990.
19. Yoshida J, Wakabayashi T, Okamoto S, et al. Tenascin in cerebrospinal fluid is a useful biomarker for the diagnosis of brain tumour. J Neurol Neurosurg Psychiatry. 1994;57:1212-1215. (Pubitemid 24321092)
20. Hasegawa M, Hirata H, Sudo A, et al. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol. 2004;31:2021-2026. (Pubitemid 39336729)
21. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;94: 1468-1470. (Pubitemid 39556230)
22. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 2002;197: 388-394. (Pubitemid 34778310)
23. Tanaka H, El-Karef A, Kaito M, et al. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver International. 2006;26:311-318. (Pubitemid 43349321)
24. Al-Tamimi YZ, Orsi NM, Quinn AC, et al. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophy-siology. World Neurosurg. 2010;73:654-667.
25. Suzuki H, Hasegawa Y, Kanamaru K, et al. Mitogen-activated protein kinases in cerebral vasospasm after subarachnoid hemorrhage: a review. Acta Neurochir Suppl. 2011;110:133-139.
26. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774-780.
27. Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145-151.
28. Ishigaki T, Imanaka-Yoshida K, Shimojo N, et al. Tenascin-C enhances crosstalk signaling of integrin avb3/PDGFR-b complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J Cell Physiol. 2011;226:2617-2624.
29. Latijnhouwers MA, Pfundt R, de Jongh GJ, et al. Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol. 1998;17:305-316. (Pubitemid 28403344)
30. Mackie EJ, Abraham LA, Taylor SL, et al. Regulation of tenascin-C expression in bone cells by transforming growth factor-beta. Bone. 1998;22:301-307. (Pubitemid 28177181)
31. McCachren SS, Lightner VA. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum. 1992;35:1185-1196.
32. Mettouchi A, Cabon F, Montreau N, et al. The c-Jun-induced transformation process involves complex regulation of tenascin-C expression. Mol Cell Biol. 1997;17:3202-3209. (Pubitemid 27215035)
33. Jinnin M, Ihn H, Asano Y, et al. Platelet derived growth factor induced tenascin-C transcription is phosphoinositide 3-kinase/Akt-dependent and mediated by Ets family transcription factors. J Cell Physiol. 2006;206:718-727. (Pubitemid 43191047)
34. Yang Y, Dang D, Mogi S, et al. Tenascin-C deposition requires b3 integrin and Src. Biochem Biophys Res Commun. 2004;322:935-942. (Pubitemid 39164443)
35. Yamamoto K, Onoda K, Sawada Y, et al. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardio-vasc Res. 2005;65:737-742. (Pubitemid 40138995)
36. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res. 1996;79: 1131-1142. (Pubitemid 26404145)
37. Imanaka-Yoshida K, Hiroe M, Nishikawa T, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 2001;81:1015-1024. (Pubitemid 32645977)
38. Imanaka-Yoshida K, Matsuura R, Isaka N, et al. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch. 2001;439:185-190. (Pubitemid 32758912)
39. Toma N, Imanaka-Yoshida K, Takeuchi T, et al. Tenascin-C coated on platinum coils accelerates organization of cavities and reduces lumen size in a rat aneurysm model. J Neurosurg. 2005;103:681-686. (Pubitemid 43193875)
40. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol. 2005;167:71-80. (Pubitemid 40884771)
41. Midwood KS, Schwarzbauer JE. Tenascin-C modulates matrix contraction via focal adhesion kinase-and rho-mediated signaling pathways. Mol Biol Cell. 2002;13:3601-3613. (Pubitemid 35191378)
42. Yamaguchi-Okada M, Nishizawa S, Koide M, et al. Biomechanical and phenotypic changes in the vasospastic canine basilar artery after subarachnoid hemorrhage. J Appl Physiol. 2005;99:2045-2052 (Pubitemid 41547208)